Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis
Диагностика нейронального цероидного липофусциноза 2-го типа (болезни CLN2): рекомендации экспертов по раннему выявлению и лабораторной диагностике
2016-07-26
SCID: 54.1/yzzhtk49
Discuss with AI
CLN2 diseaseTPP1 enzyme activityTPP1/CLN2 gene mutationslysosomal storage disordersneuronal ceroid lipofuscinosis
Figures from the paper
Abstract (AI)
Neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders. NCLs include the rare autosomal recessive neurodegenerative disorder neuronal ceroid lipofuscinosis type 2 (CLN2) disease, caused by mutations in the tripeptidyl peptidase 1 (TPP1)/CLN2 gene and the resulting TPP1 enzyme deficiency. CLN2 disease most commonly presents with seizures and/or ataxia in the late-infantile period (ages 2-4), often in combination with a history of language delay, followed by progressive childhood dementia, motor and visual deterioration, and early death. Atypical phenotypes are characterized by later onset and, in some instances, longer life expectancies. Early diagnosis is important to optimize clinical care and improve outcomes; however, currently, delays in diagnosis are common due to low disease awareness, nonspecific clinical presentation, and limited access to diagnostic testing in some regions. In May 2015, international experts met to recommend best laboratory practices for early diagnosis of CLN2 disease. When clinical signs suggest an NCL, TPP1 enzyme activity should be among the first tests performed (together with the palmitoyl-protein thioesterase enzyme activity assay to rule out CLN1 disease). However, reaching an initial suspicion of an NCL or CLN2 disease can be challenging; thus, use of an epilepsy gene panel for investigation of unexplained seizures in the late-infantile/childhood ages is encouraged. To confirm clinical suspicion of CLN2 disease, the recommended gold standard for laboratory diagnosis is demonstration of deficient TPP1 enzyme activity (in leukocytes, fibroblasts, or dried blood spots) and the identification of causative mutations in each allele of the TPP1/CLN2 gene. When it is not possible to perform both analyses, either demonstration of a) deficient TPP1 enzyme activity in leukocytes or fibroblasts, or b) detection of two pathogenic mutations in trans is diagnostic for CLN2 disease.
Key Findings
1
CLN2 disease is an autosomal recessive neurodegenerative lysosomal disorder caused by TPP1/CLN2 mutations and resulting TPP1 enzyme deficiency.
2
Diagnosis is frequently delayed because of low awareness, nonspecific presentations, and limited access to testing; early detection is important for optimizing care and outcomes.
3
For suspected NCL, TPP1 enzyme activity should be an initial test alongside palmitoyl-protein thioesterase activity to help exclude CLN1 disease; epilepsy gene panels are encouraged for unexplained late-infantile or childhood seizures.
4
The diagnostic gold standard combines deficient TPP1 activity in leukocytes, fibroblasts, or dried blood spots with pathogenic TPP1/CLN2 mutations in both alleles; either deficient leukocyte or fibroblast activity or two pathogenic mutations in trans is diagnostic when both tests cannot be performed.
5
Typical CLN2 presentation includes seizures or ataxia at ages 2–4, often with language delay, followed by progressive dementia, motor and visual deterioration, and early death.
Research Object
neuronal ceroid lipofuscinosis type 2 (CLN2) disease
Research Subject
early detection and laboratory diagnosis of CLN2 disease, including deficient TPP1 enzyme activity and pathogenic TPP1/CLN2 mutations
Publication Details
Publication Date
2016-07-26
Journal
Publisher
ISSN
Cited by
107
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest